Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy. - Penny HL; Hainline K; Theoharis N; Wu B; Brandl C; Webhofer C; McComb M; Wittemer-Rump S; Koca G; Stienen S; Bargou RC; Hummel HD; et al. (Frontiers in immunology, 2023)